Form 4: Monopar Therapeutics COO Andrew Cittadine Reports Stock Transactions
SEC Form 4
Andrew Cittadine, COO of Monopar Therapeutics, reports the acquisition and disposal of common stock related to the vesting of restricted stock units.
Summary
- On September 30, 2024, Andrew Cittadine, the Chief Operating Officer of Monopar Therapeutics, reported transactions involving the company's common stock.
- These transactions involved the vesting and settlement of restricted stock units (RSUs).
- Specifically, 1,791 shares were acquired upon the vesting of RSUs.
- 535 shares were withheld by the issuer to cover withholding taxes due upon the vesting of these RSUs at a price of $6.74.
- Following these transactions, Cittadine directly owns 39,869 shares of Monopar Therapeutics common stock.
- The reported transactions reflect adjustments for a 5-for-1 reverse stock split that took effect on August 12, 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the filing simply reports routine stock transactions related to executive compensation. There is no indication of positive or negative performance.
Positives
- The vesting of restricted stock units suggests that the COO is meeting performance milestones.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation.
Key Dates
| Date | Description |
|---|---|
| February 2, 2022 | Reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. |
| February 1, 2023 | Reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. |
| August 12, 2024 | Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock. |
| September 30, 2024 | Date of the reported stock transactions (acquisition and disposal of shares). |
| October 02, 2024 | Date of the Form 4 filing. |
| December 31, 2025 | Date when the restricted stock units granted on February 2, 2022 are fully vested. |
| December 31, 2026 | Date when the restricted stock units granted on February 1, 2023 are fully vested. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.